Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia

Young-Hoon Ko, Sook Haeng Joe, Woong Cho, Jeong Hyun Park, Jung Jae Lee, In Kwa Jung, Leen Kim, Seung Hyun Kim

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective. The purpose of this investigation was to assess the cognitive effects of adjuvant hormone replacement therapy (HRT) when used to treat premenopausal women with chronic schizophrenia using an 8-week, double-blind, placebo-controlled, randomized trial. Method. Women of childbearing age with chronic schizophrenia were recruited and randomized into placebo and HRT groups, the latter of which was administered 0.625 mg of conjugated oestrogen with 2.5 mg of medroxyprogesterone acetate daily. Each group contained 14 subjects. The principal outcome measure was a cognitive function assessment comprised of the following; the Immediate Visual Recognition Scale, List Recall Scale, Oral Fluency Test, Trail-Making Tests A and B, and Digit Symbol Test. Psychopathology was measured using the Scale for the Assessment of Negative Symptoms (SANS) and the Calgary Depression Scale for Schizophrenia. Extrapyramidal symptoms were evaluated using the Drug-Induced Extra-Pyramidal Symptoms Scale. Results. Improvements in SANS and in cognitive function as assessed using the List Recall Scale, Oral Fluency Test, and Trail-Making Test A, were significantly greater in the HRT group than in the placebo group. Conclusion. The results of this study suggest that short-term HRT is an effective adjuvant modality for improving cognitive function in women of childbearing age with chronic schizophrenia.

Original languageEnglish
Pages (from-to)97-104
Number of pages8
JournalInternational Journal of Psychiatry in Clinical Practice
Volume10
Issue number2
DOIs
Publication statusPublished - 2006 Jun 1

Fingerprint

Hormone Replacement Therapy
Cognition
Schizophrenia
Trail Making Test
Symptom Assessment
Placebos
Conjugated (USP) Estrogens
Medroxyprogesterone Acetate
Psychopathology
Randomized Controlled Trials
Outcome Assessment (Health Care)
Depression
Pharmaceutical Preparations

Keywords

  • Cognitive function
  • Negative symptoms
  • Oestrogen
  • Schizophrenia
  • Women

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia. / Ko, Young-Hoon; Joe, Sook Haeng; Cho, Woong; Park, Jeong Hyun; Lee, Jung Jae; Jung, In Kwa; Kim, Leen; Kim, Seung Hyun.

In: International Journal of Psychiatry in Clinical Practice, Vol. 10, No. 2, 01.06.2006, p. 97-104.

Research output: Contribution to journalArticle

@article{0316972cb0304e63a57ac4a919cac45e,
title = "Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia",
abstract = "Objective. The purpose of this investigation was to assess the cognitive effects of adjuvant hormone replacement therapy (HRT) when used to treat premenopausal women with chronic schizophrenia using an 8-week, double-blind, placebo-controlled, randomized trial. Method. Women of childbearing age with chronic schizophrenia were recruited and randomized into placebo and HRT groups, the latter of which was administered 0.625 mg of conjugated oestrogen with 2.5 mg of medroxyprogesterone acetate daily. Each group contained 14 subjects. The principal outcome measure was a cognitive function assessment comprised of the following; the Immediate Visual Recognition Scale, List Recall Scale, Oral Fluency Test, Trail-Making Tests A and B, and Digit Symbol Test. Psychopathology was measured using the Scale for the Assessment of Negative Symptoms (SANS) and the Calgary Depression Scale for Schizophrenia. Extrapyramidal symptoms were evaluated using the Drug-Induced Extra-Pyramidal Symptoms Scale. Results. Improvements in SANS and in cognitive function as assessed using the List Recall Scale, Oral Fluency Test, and Trail-Making Test A, were significantly greater in the HRT group than in the placebo group. Conclusion. The results of this study suggest that short-term HRT is an effective adjuvant modality for improving cognitive function in women of childbearing age with chronic schizophrenia.",
keywords = "Cognitive function, Negative symptoms, Oestrogen, Schizophrenia, Women",
author = "Young-Hoon Ko and Joe, {Sook Haeng} and Woong Cho and Park, {Jeong Hyun} and Lee, {Jung Jae} and Jung, {In Kwa} and Leen Kim and Kim, {Seung Hyun}",
year = "2006",
month = "6",
day = "1",
doi = "10.1080/13651500500526235",
language = "English",
volume = "10",
pages = "97--104",
journal = "International Journal of Psychiatry in Clinical Practice",
issn = "1365-1501",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Effect of hormone replacement therapy on cognitive function in women with chronic schizophrenia

AU - Ko, Young-Hoon

AU - Joe, Sook Haeng

AU - Cho, Woong

AU - Park, Jeong Hyun

AU - Lee, Jung Jae

AU - Jung, In Kwa

AU - Kim, Leen

AU - Kim, Seung Hyun

PY - 2006/6/1

Y1 - 2006/6/1

N2 - Objective. The purpose of this investigation was to assess the cognitive effects of adjuvant hormone replacement therapy (HRT) when used to treat premenopausal women with chronic schizophrenia using an 8-week, double-blind, placebo-controlled, randomized trial. Method. Women of childbearing age with chronic schizophrenia were recruited and randomized into placebo and HRT groups, the latter of which was administered 0.625 mg of conjugated oestrogen with 2.5 mg of medroxyprogesterone acetate daily. Each group contained 14 subjects. The principal outcome measure was a cognitive function assessment comprised of the following; the Immediate Visual Recognition Scale, List Recall Scale, Oral Fluency Test, Trail-Making Tests A and B, and Digit Symbol Test. Psychopathology was measured using the Scale for the Assessment of Negative Symptoms (SANS) and the Calgary Depression Scale for Schizophrenia. Extrapyramidal symptoms were evaluated using the Drug-Induced Extra-Pyramidal Symptoms Scale. Results. Improvements in SANS and in cognitive function as assessed using the List Recall Scale, Oral Fluency Test, and Trail-Making Test A, were significantly greater in the HRT group than in the placebo group. Conclusion. The results of this study suggest that short-term HRT is an effective adjuvant modality for improving cognitive function in women of childbearing age with chronic schizophrenia.

AB - Objective. The purpose of this investigation was to assess the cognitive effects of adjuvant hormone replacement therapy (HRT) when used to treat premenopausal women with chronic schizophrenia using an 8-week, double-blind, placebo-controlled, randomized trial. Method. Women of childbearing age with chronic schizophrenia were recruited and randomized into placebo and HRT groups, the latter of which was administered 0.625 mg of conjugated oestrogen with 2.5 mg of medroxyprogesterone acetate daily. Each group contained 14 subjects. The principal outcome measure was a cognitive function assessment comprised of the following; the Immediate Visual Recognition Scale, List Recall Scale, Oral Fluency Test, Trail-Making Tests A and B, and Digit Symbol Test. Psychopathology was measured using the Scale for the Assessment of Negative Symptoms (SANS) and the Calgary Depression Scale for Schizophrenia. Extrapyramidal symptoms were evaluated using the Drug-Induced Extra-Pyramidal Symptoms Scale. Results. Improvements in SANS and in cognitive function as assessed using the List Recall Scale, Oral Fluency Test, and Trail-Making Test A, were significantly greater in the HRT group than in the placebo group. Conclusion. The results of this study suggest that short-term HRT is an effective adjuvant modality for improving cognitive function in women of childbearing age with chronic schizophrenia.

KW - Cognitive function

KW - Negative symptoms

KW - Oestrogen

KW - Schizophrenia

KW - Women

UR - http://www.scopus.com/inward/record.url?scp=33745059338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745059338&partnerID=8YFLogxK

U2 - 10.1080/13651500500526235

DO - 10.1080/13651500500526235

M3 - Article

AN - SCOPUS:33745059338

VL - 10

SP - 97

EP - 104

JO - International Journal of Psychiatry in Clinical Practice

JF - International Journal of Psychiatry in Clinical Practice

SN - 1365-1501

IS - 2

ER -